MARKET

LGVN

LGVN

Longeveron Inc
NASDAQ
1.670
-0.080
-4.57%
Closed 16:00 10/30 EDT
OPEN
1.780
PREV CLOSE
1.750
HIGH
1.800
LOW
1.581
VOLUME
80.81K
TURNOVER
0
52 WEEK HIGH
12.30
52 WEEK LOW
1.310
MARKET CAP
5.32M
P/E (TTM)
-0.1628
1D
5D
1M
3M
1Y
5Y
1D
Longeveron Reports Fewer Cardiac Events In Phase 2b Heart Syndrome Trial After Primary Endpoint Miss
NASDAQ · 5d ago
Longeveron Highlights Positive HLHS Trial Safety Findings
TipRanks · 6d ago
Longeveron reports ELPIS II trial misses primary endpoint
TipRanks · 6d ago
Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome
Benzinga · 6d ago
Weekly Report: what happened at LGVN last week (1019-1023)?
Weekly Report · 10/26 09:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/22 21:05
Weekly Report: what happened at LGVN last week (1012-1016)?
Weekly Report · 10/19 09:58
Longeveron Announces Chief Medical Officer Leadership Transition
TipRanks · 10/14 20:31
More
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Webull offers Longeveron Inc stock information, including NASDAQ: LGVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGVN stock methods without spending real money on the virtual paper trading platform.